Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene S Pennacchietti, P Michieli, M Galluzzo, M Mazzone, S Giordano, ... Cancer cell 3 (4), 347-361, 2003 | 1595 | 2003 |
Anti-PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels C Fischer, B Jonckx, M Mazzone, S Zacchigna, S Loges, L Pattarini, ... Cell 131 (3), 463-475, 2007 | 959 | 2007 |
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization M Mazzone, D Dettori, RL de Oliveira, S Loges, T Schmidt, B Jonckx, ... Cell 136 (5), 839-851, 2009 | 941 | 2009 |
α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming PS Liu, H Wang, X Li, T Chao, T Teav, S Christen, G Di Conza, WC Cheng, ... Nature immunology 18 (9), 985-994, 2017 | 839 | 2017 |
HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF C Rolny, M Mazzone, S Tugues, D Laoui, I Johansson, C Coulon, ... Cancer cell 19 (1), 31-44, 2011 | 803 | 2011 |
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? C Fischer, M Mazzone, B Jonckx, P Carmeliet Nature Reviews Cancer 8 (12), 942-956, 2008 | 722 | 2008 |
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity A Casazza, D Laoui, M Wenes, S Rizzolio, N Bassani, M Mambretti, ... Cancer cell 24 (6), 695-709, 2013 | 656 | 2013 |
Tumour hypoxia causes DNA hypermethylation by reducing TET activity B Thienpont, J Steinbacher, H Zhao, F D’Anna, A Kuchnio, A Ploumakis, ... Nature 537 (7618), 63-68, 2016 | 607 | 2016 |
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism J Aragonés, M Schneider, K Van Geyte, P Fraisl, T Dresselaers, ... Nature genetics 40 (2), 170-180, 2008 | 568 | 2008 |
Regulation of angiogenesis by oxygen and metabolism P Fraisl, M Mazzone, T Schmidt, P Carmeliet Developmental cell 16 (2), 167-179, 2009 | 567 | 2009 |
Role and therapeutic potential of VEGF in the nervous system C Ruiz de Almodovar, D Lambrechts, M Mazzone, P Carmeliet Physiological reviews 89 (2), 607-648, 2009 | 565 | 2009 |
The impact of hypoxia on tumor-associated macrophages AT Henze, M Mazzone The Journal of clinical investigation 126 (10), 3672-3679, 2016 | 518 | 2016 |
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited S Loges, M Mazzone, P Hohensinner, P Carmeliet Cancer cell 15 (3), 167-170, 2009 | 484 | 2009 |
MET is required for the recruitment of anti-tumoural neutrophils V Finisguerra, G Di Conza, M Di Matteo, J Serneels, S Costa, ... Nature 522 (7556), 349-353, 2015 | 459 | 2015 |
Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis M Wenes, M Shang, M Di Matteo, J Goveia, R Martín-Pérez, J Serneels, ... Cell metabolism 24 (5), 701-715, 2016 | 451 | 2016 |
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population D Laoui, E Van Overmeire, G Di Conza, C Aldeni, J Keirsse, Y Morias, ... Cancer research 74 (1), 24-30, 2014 | 444 | 2014 |
An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates J Goveia, K Rohlenova, F Taverna, L Treps, LC Conradi, A Pircher, ... Cancer cell 37 (1), 21-36. e13, 2020 | 383 | 2020 |
Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting F Langlet, BE Levin, S Luquet, M Mazzone, A Messina, AA Dunn-Meynell, ... Cell metabolism 17 (4), 607-617, 2013 | 369 | 2013 |
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor P Michieli, M Mazzone, C Basilico, S Cavassa, A Sottile, L Naldini, ... Cancer cell 6 (1), 61-73, 2004 | 354 | 2004 |
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? K De Bock, M Mazzone, P Carmeliet Nature reviews Clinical oncology 8 (7), 393-404, 2011 | 346 | 2011 |